Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro.
Identifieur interne : 002346 ( PubMed/Corpus ); précédent : 002345; suivant : 002347Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro.
Auteurs : Joanna Zorzitto ; Carole L. Galligan ; Joanna J M. Ueng ; Eleanor N. FishSource :
- Cell research [ 1001-0602 ] ; 2006.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (immunology), Antiviral Agents (therapeutic use), Cell Line, Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Enzyme Inhibitors (metabolism), Gene Expression Profiling, Humans, Interferon-alpha (immunology), Interferon-alpha (therapeutic use), Janus Kinase 1 (antagonists & inhibitors), Janus Kinase 1 (metabolism), Mice, Murine hepatitis virus (immunology), Oligonucleotide Array Sequence Analysis, Protein Kinase C-delta (antagonists & inhibitors), Protein Kinase C-delta (metabolism), SARS Virus (immunology), p38 Mitogen-Activated Protein Kinases (antagonists & inhibitors), p38 Mitogen-Activated Protein Kinases (metabolism).
- MESH :
- chemical , antagonists & inhibitors : Janus Kinase 1, Protein Kinase C-delta, p38 Mitogen-Activated Protein Kinases.
- chemical , immunology : Antiviral Agents, Interferon-alpha.
- chemical , metabolism : Enzyme Inhibitors, Janus Kinase 1, Protein Kinase C-delta, p38 Mitogen-Activated Protein Kinases.
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha.
- drug therapy : Coronavirus Infections.
- immunology : Coronavirus Infections, Murine hepatitis virus, SARS Virus.
- Animals, Cell Line, Gene Expression Profiling, Humans, Mice, Oligonucleotide Array Sequence Analysis.
Abstract
Interferon (IFN)-alphas bind to and activate their cognate cell surface receptor to invoke an antiviral response in target cells. Well-described receptor-mediated signaling events result in transcriptional regulation of IFN sensitive genes, effectors of this antiviral response. Results from a pilot study to evaluate the clinical efficacy of IFN-alpha treatment of SARS patients provided evidence for IFN-inducible resolution of disease. In this report we examined the contribution of IFN-inducible phosphorylation-activation of specific signaling effectors to protection from infection by a SARS-related murine coronavirus, MHV-1. As anticipated, the earliest receptor-activation event, Jak1 phosphorylation, is critical for IFN-inducible protection from MHV-1 infection. Additionally, we provide evidence for the contribution of two kinases, the MAP kinase p38MAPK, and protein kinase C (PKC) delta to antiviral protection from MHV-1 infection. Notably, our data suggest that MHV-1 infection, as for the Urbani SARS coronoavirus, inhibits an IFN response, inferred from the lack of activation of pkr and 2'5'-oas, genes associated with mediating the antiviral activities of IFN-alphas. To identify potential target genes that are activated downstream of the IFN-inducible signaling effectors we identified, and that mediate protection from coronavirus infection, we examined the gene expression profiles in the peripheral blood mononuclear cells of SARS patients who received IFN treatment. A subset of differentially regulated genes were distinguished with functional properties associated with antimicrobial activities.
DOI: 10.1038/sj.cr.7310030
PubMed: 16474437
Links to Exploration step
pubmed:16474437Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro.</title><author><name sortKey="Zorzitto, Joanna" sort="Zorzitto, Joanna" uniqKey="Zorzitto J" first="Joanna" last="Zorzitto">Joanna Zorzitto</name><affiliation><nlm:affiliation>Department of Immunology, University of Toronto, Toronto, Ontario, M5G 2M1, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Galligan, Carole L" sort="Galligan, Carole L" uniqKey="Galligan C" first="Carole L" last="Galligan">Carole L. Galligan</name></author><author><name sortKey="Ueng, Joanna J M" sort="Ueng, Joanna J M" uniqKey="Ueng J" first="Joanna J M" last="Ueng">Joanna J M. Ueng</name></author><author><name sortKey="Fish, Eleanor N" sort="Fish, Eleanor N" uniqKey="Fish E" first="Eleanor N" last="Fish">Eleanor N. Fish</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16474437</idno><idno type="pmid">16474437</idno><idno type="doi">10.1038/sj.cr.7310030</idno><idno type="wicri:Area/PubMed/Corpus">002346</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002346</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro.</title><author><name sortKey="Zorzitto, Joanna" sort="Zorzitto, Joanna" uniqKey="Zorzitto J" first="Joanna" last="Zorzitto">Joanna Zorzitto</name><affiliation><nlm:affiliation>Department of Immunology, University of Toronto, Toronto, Ontario, M5G 2M1, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Galligan, Carole L" sort="Galligan, Carole L" uniqKey="Galligan C" first="Carole L" last="Galligan">Carole L. Galligan</name></author><author><name sortKey="Ueng, Joanna J M" sort="Ueng, Joanna J M" uniqKey="Ueng J" first="Joanna J M" last="Ueng">Joanna J M. Ueng</name></author><author><name sortKey="Fish, Eleanor N" sort="Fish, Eleanor N" uniqKey="Fish E" first="Eleanor N" last="Fish">Eleanor N. Fish</name></author></analytic><series><title level="j">Cell research</title><idno type="ISSN">1001-0602</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (immunology)</term><term>Antiviral Agents (therapeutic use)</term><term>Cell Line</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Enzyme Inhibitors (metabolism)</term><term>Gene Expression Profiling</term><term>Humans</term><term>Interferon-alpha (immunology)</term><term>Interferon-alpha (therapeutic use)</term><term>Janus Kinase 1 (antagonists & inhibitors)</term><term>Janus Kinase 1 (metabolism)</term><term>Mice</term><term>Murine hepatitis virus (immunology)</term><term>Oligonucleotide Array Sequence Analysis</term><term>Protein Kinase C-delta (antagonists & inhibitors)</term><term>Protein Kinase C-delta (metabolism)</term><term>SARS Virus (immunology)</term><term>p38 Mitogen-Activated Protein Kinases (antagonists & inhibitors)</term><term>p38 Mitogen-Activated Protein Kinases (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Janus Kinase 1</term><term>Protein Kinase C-delta</term><term>p38 Mitogen-Activated Protein Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Enzyme Inhibitors</term><term>Janus Kinase 1</term><term>Protein Kinase C-delta</term><term>p38 Mitogen-Activated Protein Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Murine hepatitis virus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Gene Expression Profiling</term><term>Humans</term><term>Mice</term><term>Oligonucleotide Array Sequence Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interferon (IFN)-alphas bind to and activate their cognate cell surface receptor to invoke an antiviral response in target cells. Well-described receptor-mediated signaling events result in transcriptional regulation of IFN sensitive genes, effectors of this antiviral response. Results from a pilot study to evaluate the clinical efficacy of IFN-alpha treatment of SARS patients provided evidence for IFN-inducible resolution of disease. In this report we examined the contribution of IFN-inducible phosphorylation-activation of specific signaling effectors to protection from infection by a SARS-related murine coronavirus, MHV-1. As anticipated, the earliest receptor-activation event, Jak1 phosphorylation, is critical for IFN-inducible protection from MHV-1 infection. Additionally, we provide evidence for the contribution of two kinases, the MAP kinase p38MAPK, and protein kinase C (PKC) delta to antiviral protection from MHV-1 infection. Notably, our data suggest that MHV-1 infection, as for the Urbani SARS coronoavirus, inhibits an IFN response, inferred from the lack of activation of pkr and 2'5'-oas, genes associated with mediating the antiviral activities of IFN-alphas. To identify potential target genes that are activated downstream of the IFN-inducible signaling effectors we identified, and that mediate protection from coronavirus infection, we examined the gene expression profiles in the peripheral blood mononuclear cells of SARS patients who received IFN treatment. A subset of differentially regulated genes were distinguished with functional properties associated with antimicrobial activities.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16474437</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1001-0602</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Cell research</Title><ISOAbbreviation>Cell Res.</ISOAbbreviation></Journal><ArticleTitle>Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro.</ArticleTitle><Pagination><MedlinePgn>220-9</MedlinePgn></Pagination><Abstract><AbstractText>Interferon (IFN)-alphas bind to and activate their cognate cell surface receptor to invoke an antiviral response in target cells. Well-described receptor-mediated signaling events result in transcriptional regulation of IFN sensitive genes, effectors of this antiviral response. Results from a pilot study to evaluate the clinical efficacy of IFN-alpha treatment of SARS patients provided evidence for IFN-inducible resolution of disease. In this report we examined the contribution of IFN-inducible phosphorylation-activation of specific signaling effectors to protection from infection by a SARS-related murine coronavirus, MHV-1. As anticipated, the earliest receptor-activation event, Jak1 phosphorylation, is critical for IFN-inducible protection from MHV-1 infection. Additionally, we provide evidence for the contribution of two kinases, the MAP kinase p38MAPK, and protein kinase C (PKC) delta to antiviral protection from MHV-1 infection. Notably, our data suggest that MHV-1 infection, as for the Urbani SARS coronoavirus, inhibits an IFN response, inferred from the lack of activation of pkr and 2'5'-oas, genes associated with mediating the antiviral activities of IFN-alphas. To identify potential target genes that are activated downstream of the IFN-inducible signaling effectors we identified, and that mediate protection from coronavirus infection, we examined the gene expression profiles in the peripheral blood mononuclear cells of SARS patients who received IFN treatment. A subset of differentially regulated genes were distinguished with functional properties associated with antimicrobial activities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zorzitto</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology, University of Toronto, Toronto, Ontario, M5G 2M1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galligan</LastName><ForeName>Carole L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Ueng</LastName><ForeName>Joanna J M</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Fish</LastName><ForeName>Eleanor N</ForeName><Initials>EN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Res</MedlineTA><NlmUniqueID>9425763</NlmUniqueID><ISSNLinking>1001-0602</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="C507905">Jak1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D053613">Janus Kinase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D051745">Protein Kinase C-delta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="Y">Interferon-alpha</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053613" MajorTopicYN="N">Janus Kinase 1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006517" MajorTopicYN="N">Murine hepatitis virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051745" MajorTopicYN="N">Protein Kinase C-delta</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16474437</ArticleId><ArticleId IdType="pii">7310030</ArticleId><ArticleId IdType="doi">10.1038/sj.cr.7310030</ArticleId><ArticleId IdType="pmc">PMC7091892</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Immunity. 2001 Jun;14(6):661-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11420036</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Aug 27;321(3):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15358166</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EMBO J. 1999 Oct 15;18(20):5601-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10523304</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 1986 Sep;154(3):443-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3016111</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Forum (Genova). 2001 Apr-Jun;11(2):154-62</Citation><ArticleIdList><ArticleId IdType="pubmed">11948360</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Retrovirology. 2004 Dec 08;1:42</Citation><ArticleIdList><ArticleId IdType="pubmed">15588285</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2002 Apr 26;277(17):14408-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11839738</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 1994 Feb 4;269(5):3143-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7508909</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 1986 Oct;18 Suppl B:153-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3025154</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2000 Aug;47(2):131-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10996401</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Cytokine Res. 2000 Jul;20(7):653-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10926208</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2003 Dec;1(3):209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15035025</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Cytokine Res. 2002 Aug;22(8):835-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12396722</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 1974 May 2;290(18):996-1002</Citation><ArticleIdList><ArticleId IdType="pubmed">4362084</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Neurovirol. 2002 Apr;8(2):76-85</Citation><ArticleIdList><ArticleId IdType="pubmed">11935460</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Biochem. 1998;67:227-64</Citation><ArticleIdList><ArticleId IdType="pubmed">9759489</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2004 Dec 20;330(2):471-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15567440</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2002 Nov 1;298(5595):995-1000</Citation><ArticleIdList><ArticleId IdType="pubmed">12351674</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Res. 1992 Aug;12(4):237-40</Citation><ArticleIdList><ArticleId IdType="pubmed">1385551</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2001 Aug 10;276(32):30178-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11487589</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1983 Nov;24(5):713-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6318655</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2003 Aug 1;312(2):395-406</Citation><ArticleIdList><ArticleId IdType="pubmed">12919744</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>IUBMB Life. 2005 Feb;57(2):65-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16036565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Immun. 1972 Oct;6(4):501-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4564284</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2001 Jul 27;276(30):28570-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11353767</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents</Citation><ArticleIdList><ArticleId IdType="pubmed">11585785</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 May;79(9):5241-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15827138</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Cytokine Res. 2004 Aug;24(8):439-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15320958</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Biochem. 1987;56:727-77</Citation><ArticleIdList><ArticleId IdType="pubmed">2441659</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Cytokine Res. 1996 Jul;16(7):489-99</Citation><ArticleIdList><ArticleId IdType="pubmed">8836913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2004 Nov 10;329(1):11-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15476870</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Cytokine Res. 2004 Feb;24(2):107-18</Citation><ArticleIdList><ArticleId IdType="pubmed">14980075</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):317-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15030704</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Feb;79(4):2079-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15681410</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lab Anim Sci. 1986 Apr;36(2):130-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3009966</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Oct;74(19):8793-802</Citation><ArticleIdList><ArticleId IdType="pubmed">10982321</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1988 Jul;165(1):87-94</Citation><ArticleIdList><ArticleId IdType="pubmed">2455384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Invest. 2005 Mar;115(3):765-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15719067</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Cell Biol. 1998 Feb;18(2):859-71</Citation><ArticleIdList><ArticleId IdType="pubmed">9447982</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 1999 Oct 15;274(42):30127-31</Citation><ArticleIdList><ArticleId IdType="pubmed">10514501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1997 Mar 1;158(5):2390-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9036989</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 1999 Jan 8;274(2):571-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9872990</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Immunol. 2004 Oct;5(10):1061-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15361868</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6764-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9192639</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2005 May;5(5):375-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15864272</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):143-56</Citation><ArticleIdList><ArticleId IdType="pubmed">11325598</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jun 14;361(9374):2045-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12814717</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drugs. 2001;61(11):1661-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11577799</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Infect Dis. 2001 Oct;14(5):593-601</Citation><ArticleIdList><ArticleId IdType="pubmed">11964881</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Ther. 2004 Dec;9(6):1003-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15651759</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Res. 1989 Jun;9(3):285-93</Citation><ArticleIdList><ArticleId IdType="pubmed">2545792</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Mar;10(3):290-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14981511</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Cytokine Res. 2004 Jul;24(7):388-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15296649</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1164-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15031783</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1975 Oct 30;257(5529):799-800</Citation><ArticleIdList><ArticleId IdType="pubmed">1186865</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15623-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9861020</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002346 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002346 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16474437
|texte= Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16474437" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |